Gilead CEO: Remdesivir Priced ‘Significantly’ Below Value to Society
Sydney Otomancek2023-11-15T16:53:04-05:00July 1st, 2020|Categories: Featured, HEOR Feature, Industry News|Tags: COVID-19, Daniel O'Day, Gilead, Healtheconomics.com, HEOR, Peter Bach, remdesivir|
Gilead CEO Daniel O'Day told STAT he's confident in the company's pricing decision for the COVID-19 drug remdesivir. "We spent [...]
MSK’s Bach Talks High-Value Drug Development
Sydney Otomancek2023-11-15T16:54:28-05:00April 2nd, 2020|Categories: Featured, HEOR Feature, Industry News|Tags: drug development, Healtheconomics.com, HEOR, Peter Bach, pharma|
Memorial Sloan Kettering Cancer Center's Dr. Peter Bach in a recent interview with Liam Bendicksen discusses ways to optimize high-value [...]
Receive essential insights, resources and content direct to your inbox!
Hit subscribe to stay informed!
Advertisement
Latest News
Featured Webinars
Navigating the Clinical Outcomes Maze: An Overview of Clinical Outcomes Assessments and Why Training Matters
Tuesday, December 5, 2023
Sponsor: ICON
EU HTA Joint Clinical Assessments: Navigating Potential Challenges Ahead of 2025
Friday, November 10, 2023
Sponsor: OpenHealth
Cell & Gene Therapies – Beginning with the End in Mind
Thursday, November 2, 2023
Sponsor: Magnolia Market Access
Categories
Artificial Intelligence
Careers
Clinical Trials
Cost Effectiveness
Data Analytics & Syndicated Reports
Healthcare Financing
Health Databases
Health Equity
Health Policy
Health Tech Assessment
Integrated Evidence Assessment & Planning
Market Access
Medical Affairs
Patient Outcomes & Engagement
Pricing & Reimbursement
Real World Data
Real World Evidence
Value Assessment
Value Communication